Russell Investments Group Ltd. lowered its holdings in Quest Diagnostics Incorporated (NYSE:DGX – Free Report) by 7.1% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 95,037 shares of the medical research company’s stock after selling 7,255 shares during the quarter. Russell Investments Group Ltd. owned 0.09% of Quest Diagnostics worth $22,146,000 at the end of the most recent quarter.
Several other hedge funds have also recently added to or reduced their stakes in DGX. R Squared Ltd bought a new position in Quest Diagnostics during the third quarter worth about $240,000. CENTRAL TRUST Co boosted its holdings in Quest Diagnostics by 136.6% during the third quarter. CENTRAL TRUST Co now owns 3,823 shares of the medical research company’s stock valued at $891,000 after purchasing an additional 2,207 shares in the last quarter. Fifth Third Bancorp grew its stake in shares of Quest Diagnostics by 2.0% in the 3rd quarter. Fifth Third Bancorp now owns 33,181 shares of the medical research company’s stock valued at $7,734,000 after purchasing an additional 641 shares during the period. Maryland State Retirement & Pension System grew its stake in shares of Quest Diagnostics by 19.0% in the 3rd quarter. Maryland State Retirement & Pension System now owns 6,870 shares of the medical research company’s stock valued at $1,601,000 after purchasing an additional 1,096 shares during the period. Finally, Jacobi Capital Management LLC bought a new stake in shares of Quest Diagnostics in the 3rd quarter valued at approximately $211,000. Institutional investors and hedge funds own 88.06% of the company’s stock.
Quest Diagnostics Price Performance
NYSE:DGX opened at $256.50 on Wednesday. The company has a quick ratio of 1.58, a current ratio of 1.70 and a debt-to-equity ratio of 0.70. The firm has a market cap of $28.22 billion, a PE ratio of 25.55, a price-to-earnings-growth ratio of 2.35 and a beta of 0.55. Quest Diagnostics Incorporated has a 12 month low of $171.18 and a 12 month high of $263.19. The company’s 50-day moving average price is $242.14 and its two-hundred day moving average price is $216.35.
Quest Diagnostics (NYSE:DGX – Get Free Report) last posted its quarterly earnings data on Thursday, October 22nd. The medical research company reported $3.00 earnings per share for the quarter, topping the consensus estimate of $2.87 by $0.13. Quest Diagnostics had a net margin of 9.53% and a return on equity of 16.21%. The company had revenue of $3.10 billion during the quarter, compared to analyst estimates of $3.05 billion. During the same quarter last year, the business posted $2.60 earnings per share. The company’s revenue was up 10.0% on a year-over-year basis. On average, equities analysts anticipate that Quest Diagnostics Incorporated will post 11.29 EPS for the current fiscal year.
Quest Diagnostics Announces Dividend
The firm also recently declared a quarterly dividend, which will be paid on Wednesday, January 27th. Investors of record on Tuesday, January 12th will be issued a dividend of $0.86 per share. This represents a $3.44 dividend on an annualized basis and a yield of 1.3%. The ex-dividend date of this dividend is Tuesday, January 12th. Quest Diagnostics’s dividend payout ratio (DPR) is currently 34.26%.
Insider Activity
In other Quest Diagnostics news, CAO Michael J. Deppe sold 11,776 shares of the business’s stock in a transaction on Friday, November 13th. The stock was sold at an average price of $260.17, for a total value of $3,063,761.92. Following the transaction, the chief accounting officer owned 35,203 shares of the company’s stock, valued at approximately $9,158,764.51. The trade was a 25.07% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Catherine T. Doherty sold 22,105 shares of the stock in a transaction on Tuesday, November 3rd. The stock was sold at an average price of $248.02, for a total value of $5,482,482.10. Following the sale, the executive vice president owned 71,949 shares in the company, valued at $17,844,790.98. The trade was a 23.50% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 79,478 shares of company stock worth $19,794,031. 0.88% of the stock is currently owned by insiders.
Analyst Upgrades and Downgrades
Several equities analysts recently commented on DGX shares. Robert W. Baird set a $262.00 target price on Quest Diagnostics in a research report on Friday, October 23rd. UBS Group reaffirmed a “neutral” rating and issued a $250.00 price target on shares of Quest Diagnostics in a research note on Monday, October 19th. Wall Street Zen upgraded Quest Diagnostics from a “hold” rating to a “buy” rating in a research report on Tuesday, July 28th. Barclays increased their price objective on Quest Diagnostics from $250.00 to $260.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 7th. Finally, Truist Financial lifted their price objective on Quest Diagnostics from $250.00 to $260.00 and gave the company a “hold” rating in a report on Monday, September 21st. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and five have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $248.70.
Check Out Our Latest Report on Quest Diagnostics
Quest Diagnostics Profile
Quest Diagnostics (NYSE: DGX) is a provider of diagnostic information services, conducting laboratory tests that help physicians and other health care professionals diagnose, monitor and manage medical conditions. Its services include routine blood and other clinical laboratory testing, anatomic pathology, and specialized molecular and genetic testing. The company serves patients, physicians, hospitals, health plans, employers and government organizations. In addition to testing performed through its laboratories and patient service centers, Quest offers services such as workplace drug testing and diagnostic support for clinical research.
Recommended Stories
- Five stocks we like better than Quest Diagnostics
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Receive News & Ratings for Quest Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.
